
NexGen Energy Ltd. (TSX: NXE) (NYSE: NXE) (ASX: NXG) is excited to announce significant geochemical assay results from NexGen’s 100%-owned Patterson Corridor East discovery.
Additional assay results contained in this release, confirm strong continuity of the high-grade subdomain (Figure 1, Table 1) over 330m in vertical extent from RK-25-246 to RK-25-231. Further, RK-25-231 (8.0m at 1.4% U3O8) and -241 (8.5m at 1.3% U3O8) demonstrate the continuity of the subdomain and add breadth while indicating extended high-grade potential. A secondary high-grade subdomain is currently interpreted from results in RK-25-234, with 0.5m at 8.3% U3O8 that lies along a potential new high-grade shoot.
Note, additional assay results from drillhole RK-25-256, which intersected intense high-grade mineralization 128m down dip of RK-25-232 and 179m from RK-25-254, are pending and will be released with further assays as they are received back from the independent lab.
PCE drilling has delivered significant advancements of a discovery that is characteristic of the southwest Athabasca Basin district, of which NexGen holds a 190,000 hectare land package. This setting has an identical technical advantage as the nearby Arrow deposit, 3.5 kilometers west of PCE, as mineralization is fully hosted in competent basement rock with dimensions that are expanding rapidly since initial discovery in February 2024. The overall mineralized footprint is currently defined as 600m along strike and 600m of vertical extent, with a high-grade subdomain of 210m in strike and 335m in vertical extent.
Leigh Curyer, Chief Executive Officer, commented: “Today’s assay results from PCE represent further validation of this new discovery. The PCE discovery and drilling program is the same bold, wide spaced, safe and cost effective approach that defined the world class Arrow deposit and is delivering results of the same calibre. It’s so exciting to be in the midst of another significant discovery.
From our world-class Arrow deposit in its final stages of Federal approvals, to PCE growing into an additional project on its own merits 3.5km east of Arrow, the NexGen team continues to deliver unparalleled and increasing leverage to the world uranium market for the coming decades. NexGen is ideally positioned for North America’s critical mineral and energy security strategy, while exemplifying elite standards in environmental performance and social engagement.”
Jason Craven, Vice President, Exploration, commented: “NexGen has executed with a systematic and impactful approach to advance PCE since discovery in February 2024. Importantly, not only are we seeing world-class uranium grades over significant widths, but also the continuity of that mineralization is incredibly strong. The repeatability of consistent high-grade results at PCE, with so much untested area remaining highlights the significant potential for continued expansion.
After more than 20 years exploring for uranium in the Basin, I never imagined I’d get the chance to work on a project like Arrow – something that was thought to be impossible prior to NexGen. To now find ourselves at the early stages of another discovery with similar characteristics and growing potential is both remarkable and deeply humbling.”

Figure 1: Interpreted PCE long section (as of last release on August 28, 2025) with notable assays collected since discovery and new results outlined in red; view is a long section that looks perpendicular to the primary mineralized plane; total mineralized footprint in orange and the high-grade subdomains in red

Figure 2: Core photo with assays from RK-25-254, grades are shown as % U3O8

Figure 3: Core photo with assays from RK-25-244, grades are shown as % U3O8
Table 1: Assays received since July 29, 2025 news release
| Drillhole | Unconformity Depth (m) | SRC Geoanalytical Results | ||||||
| (Cutoff 0.01%) | ||||||||
| Hole ID | Azimuth | Dip | Total Depth (m) | From (m) | To (m) | Width (m) | U3O8 (wt%) | |
| RK-25-229 | 350 | -70 | 681.4 | 113.2 | Assays Pending* | |||
| RK-25-230 | 330 | -70 | 598 | 112.5 | Assays Pending* | |||
| RK-25-231 | 329 | -69.5 | 885 | 102.7 | 677 | 677.5 | 0.5 | 0.03 |
| 683 | 685.5 | 2.5 | 0.07 | |||||
| 686 | 687 | 1 | 0.12 | |||||
| 687.5 | 688.5 | 1 | 1.16 | |||||
| 689 | 690.5 | 1.5 | 0.16 | |||||
| 692.5 | 700.5 | 8 | 1.42 | |||||
| incl. | 694 | 699 | 5 | 2.12 | ||||
| 701 | 702 | 1 | 0.02 | |||||
| 706.5 | 710.5 | 4 | 0.57 | |||||
| incl. | 706.5 | 707 | 0.5 | 1.24 | ||||
| incl. | 708 | 709 | 1 | 1.53 | ||||
| 712 | 712.5 | 0.5 | 0.02 | |||||
| 713 | 714 | 1 | 0.03 | |||||
| 716 | 717 | 1 | 0.20 | |||||
| 725.5 | 726 | 0.5 | 0.26 | |||||
| 729.5 | 730.5 | 1 | 0.05 | |||||
| 731.5 | 732.5 | 1 | 0.08 | |||||
| 734 | 734.5 | 0.5 | 0.19 | |||||
| 768.5 | 769 | 0.5 | 0.01 | |||||
| 769.5 | 770 | 0.5 | 0.02 | |||||
| 772 | 772.5 | 0.5 | 0.15 | |||||
| 775 | 776.5 | 1.5 | 0.02 | |||||
| 780.5 | 781.5 | 1 | 0.62 | |||||
| incl. | 780.5 | 781 | 0.5 | 1.07 | ||||
| 791 | 792 | 1 | 0.04 | |||||
| 792.5 | 794.5 | 2 | 0.42 | |||||
| RK-25-233 | 330 | -70 | 694 | 109.7 | Assays Pending* | |||
| RK-25-234 | 330 | -70 | 747 | 113 | 672 | 673.5 | 1.5 | 0.04 |
| 675 | 675.5 | 0.5 | 0.01 | |||||
| 677 | 678.5 | 1.5 | 0.02 | |||||
| 687 | 688.5 | 1.5 | 3.02 | |||||
| incl. | 687.5 | 688 | 0.5 | 8.33 | ||||
| RK-25-235 | 270 | -70 | 858 | 105.5 | Assays Pending | |||
| RK-25-236 | 267 | -65 | 541 | 129 | Assays Pending* | |||
| RK-25-237 | 340 | -70 | 816 | 104.6 | No Significant Intersections | |||
| RK-25-238a | 279 | -67 | 165 | 123.4 | No Significant Intersections | |||
| RK-25-239 | 278 | -68 | 594 | 123.4 | Assays Pending* | |||
| RK-25-240 | 270 | -70 | 893 | 106.1 | Assays Pending* | |||
| RK-25-241 | 320 | -71 | 534 | 117.2 | 396 | 396.5 | 0.5 | 0.04 |
| 413.5 | 419.5 | 6 | 0.31 | |||||
| incl. | 418 | 418.5 | 0.5 | 1.12 | ||||
| 424 | 424.5 | 0.5 | 0.13 | |||||
| 425 | 426 | 1 | 0.06 | |||||
| 427.5 | 428 | 0.5 | 0.01 | |||||
| 428.5 | 429.5 | 1 | 0.02 | |||||
| 430.5 | 431 | 0.5 | 0.01 | |||||
| 432 | 432.5 | 0.5 | 0.02 | |||||
| 434 | 439.5 | 5.5 | 0.04 | |||||
| 440 | 440.5 | 0.5 | 0.06 | |||||
| 444 | 444.5 | 0.5 | 0.09 | |||||
| 448.5 | 457 | 8.5 | 1.27 | |||||
| incl. | 449 | 450.5 | 1.5 | 5.79 | ||||
| incl. | 449.0 | 449.5 | 0.5 | 10.2 | ||||
| 462.5 | 465.5 | 3 | 0.07 | |||||
| 466 | 466.5 | 0.5 | 0.02 | |||||
| 467 | 467.5 | 0.5 | 0.04 | |||||
| 468 | 468.5 | 0.5 | 0.01 | |||||
| 469.5 | 470 | 0.5 | 0.01 | |||||
| 495 | 495.5 | 0.5 | 0.01 | |||||
| 496 | 496.5 | 0.5 | 0.02 | |||||
| 497.5 | 498.5 | 1 | 0.05 | |||||
| 501 | 501.5 | 0.5 | 0.10 | |||||
| 503 | 503.5 | 0.5 | 0.07 | |||||
| RK-25-242 | 270 | -70 | 555 | 124.5 | No Significant Intersections | |||
| RK-25-243 | 276 | -66 | 579 | 126.8 | Assays Pending* | |||
| RK-25-244 | 330 | -70 | 586.6 | 112.4 | 410 | 411 | 1 | 0.01 |
| 412 | 413.5 | 1.5 | 0.31 | |||||
| 414 | 415.5 | 1.5 | 0.02 | |||||
| 421 | 425 | 4 | 0.06 | |||||
| 428 | 429 | 1 | 0.18 | |||||
| 430 | 430.5 | 0.5 | 0.03 | |||||
| 434 | 434.5 | 0.5 | 0.01 | |||||
| 445.5 | 446 | 0.5 | 0.01 | |||||
| 453.5 | 456 | 2.5 | 0.03 | |||||
| 456.5 | 460 | 3.5 | 0.04 | |||||
| 462 | 479 | 17 | 7.63 | |||||
| incl. | 472 | 478 | 6 | 21.1 | ||||
| incl. | 475.5 | 476 | 0.5 | 58.1 | ||||
| 480 | 483.5 | 3.5 | 0.76 | |||||
| incl. | 481.5 | 482 | 0.5 | 4.22 | ||||
| 489.5 | 491 | 1.5 | 0.05 | |||||
| 492 | 492.5 | 0.5 | 0.01 | |||||
| 497 | 498 | 1 | 0.03 | |||||
| 499 | 499.5 | 0.5 | 0.02 | |||||
| 510 | 511 | 1 | 0.12 | |||||
| 528 | 531.5 | 3.5 | 0.64 | |||||
| incl. | 529 | 530 | 1 | 1.38 | ||||
| RK-25-245 | 330 | -70 | 744.0 | 111.5 | 693 | 694 | 1 | 0.01 |
| 695 | 696.5 | 1.5 | 0.04 | |||||
| 707 | 707.5 | 0.5 | 0.09 | |||||
| 724 | 724.5 | 0.5 | 0.25 | |||||
| 725 | 725.5 | 0.5 | 0.03 | |||||
| RK-25-246 | 270 | -70 | 525.0 | 124.5 | 332 | 332.5 | 0.5 | 0.02 |
| 333 | 334 | 1 | 0.02 | |||||
| 337 | 344 | 7 | 0.08 | |||||
| 367 | 370 | 3 | 0.01 | |||||
| 375.5 | 397.5 | 22 | 0.38 | |||||
| incl. | 379.5 | 385 | 5.5 | 1.06 | ||||
| 398 | 401 | 3 | 0.09 | |||||
| 402 | 405.5 | 3.5 | 0.20 | |||||
| 423 | 426 | 3 | 0.03 | |||||
| 444.5 | 447 | 2.5 | 0.02 | |||||
| 447.5 | 448.5 | 1 | 0.02 | |||||
| 450.5 | 451 | 0.5 | 0.02 | |||||
| 451.5 | 452 | 0.5 | 0.01 | |||||
| 453 | 453.5 | 0.5 | 0.02 | |||||
| 456.5 | 457 | 0.5 | 0.01 | |||||
| 458 | 458.5 | 0.5 | 0.03 | |||||
| 460.5 | 462 | 1.5 | 0.13 | |||||
| 479 | 480 | 1 | 0.14 | |||||
| 488.5 | 489.5 | 1 | 0.04 | |||||
| RK-25-247 | 330 | -70 | 738.0 | 114.4 | Assays Pending* | |||
| RK-25-248 | 283 | -69 | 501.0 | 123.3 | Assays Pending | |||
| RK-25-249 | 340 | -70 | 681.0 | 106.1 | Assays Pending* | |||
| RK-25-250 | 308 | -70 | 726.0 | 114.8 | Assays Pending* | |||
| RK-25-251 | 302 | -69 | 576.3 | 119.6 | Assays Pending* | |||
| RK-25-252 | 275 | -68 | 663.0 | 120.8 | Assays Pending* | |||
| RK-25-253 | 340 | -70 | 657.0 | 116.8 | No Significant Intersections | |||
| RK-25-254 | 275 | -65 | 582.0 | 128.0 | 404.5 | 405.5 | 1 | 0.02 |
| 406 | 406.5 | 0.5 | 0.02 | |||||
| 407 | 407.5 | 0.5 | 0.01 | |||||
| 408.5 | 409 | 0.5 | 0.02 | |||||
| 409.5 | 410 | 0.5 | 0.02 | |||||
| 410.5 | 411 | 0.5 | 0.02 | |||||
| 418.5 | 419.5 | 1 | 0.03 | |||||
| 430 | 430.5 | 0.5 | 0.02 | |||||
| 433 | 433.5 | 0.5 | 0.01 | |||||
| 434.5 | 435 | 0.5 | 0.02 | |||||
| 435.5 | 436 | 0.5 | 0.01 | |||||
| 437 | 437.5 | 0.5 | 0.02 | |||||
| 438 | 440 | 2 | 0.02 | |||||
| 440.5 | 441 | 0.5 | 0.01 | |||||
| 442 | 443.5 | 1.5 | 0.01 | |||||
| 444 | 444.5 | 0.5 | 0.02 | |||||
| 445.5 | 446 | 0.5 | 0.02 | |||||
| 447 | 447.5 | 0.5 | 0.01 | |||||
| 449 | 459.5 | 10.5 | 11.3 | |||||
| incl. | 454 | 458 | 4 | 29.4 | ||||
| incl. | 456.5 | 457 | 0.5 | 56.2 | ||||
| 462 | 463 | 1 | 0.04 | |||||
| 463.5 | 464 | 0.5 | 0.01 | |||||
| 475.5 | 477 | 1.5 | 0.01 | |||||
| 478.5 | 479 | 0.5 | 0.02 | |||||
| 480 | 481.5 | 1.5 | 0.03 | |||||
| 483 | 485 | 2 | 0.13 | |||||
| 485.5 | 487 | 1.5 | 0.05 | |||||
| 488 | 488.5 | 0.5 | 0.09 | |||||
| 489 | 491.5 | 2.5 | 0.04 | |||||
| 505 | 507.5 | 2.5 | 0.14 | |||||
| 509 | 509.5 | 0.5 | 0.01 | |||||
| 522 | 522.5 | 0.5 | 0.14 | |||||
| 536.5 | 538.5 | 2 | 0.25 | |||||
| 541.5 | 542 | 0.5 | 0.33 | |||||
| RK-25-254c1 | 275 | -65 | 564.0 | N/A | Assays Pending* | |||
| RK-25-254c2 | 275 | -65 | 553.5 | – | Assays Pending* | |||
| RK-25-255 | 4 | -70 | 950.4 | 112.7 | Assays Pending* | |||
| RK-25-256 | 292 | -65.5 | 696.0 | 116.9 | Assays Pending* | |||
About NexGen
NexGen Energy is a Canadian company focused on delivering clean energy fuel for the future. The Company’s flagship Rook I Project is being optimally developed into the largest low-cost producing uranium mine globally, incorporating the most elite environmental and social governance standards. The Rook I Project is supported by an N.I. 43-101 compliant Feasibility Study, which outlines the elite environmental performance and industry-leading economics. NexGen is led by a team of experienced uranium and mining industry professionals with expertise across the entire mining life cycle, including exploration, financing, project engineering and construction, operations and closure. NexGen is leveraging its proven experience to deliver a Project that leads the entire mining industry socially, technically and environmentally. The Project and prospective portfolio in northern Saskatchewan will provide generational, long-term economic, environmental, and social benefits for Saskatchewan, Canada, and the world.
Capella Minerals Ltd. (TSX-V: CMIL) (FRA: N7D2) is pleased to ann... READ MORE
SLAM Exploration Ltd. (TSX-V: SXL) is pleased to announce it has... READ MORE
Sitka’s initial drilling at Contact returns >100 gram-me... READ MORE
EMX Royalty Corporation (NYSE: EMX) (TSX-V: EMX) is pleased to... READ MORE
Fox River Resources Corporation (CSE: FOX) is excited to announce... READ MORE